CytomX Therapeutics, Inc. – NASDAQ:CTMX
Founder-led company
CytomX Therapeutics stock price today
$2
+0.93
+86.93%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
CytomX Therapeutics stock price monthly change
-24.65%
month
CytomX Therapeutics stock price quarterly change
-24.65%
quarter
CytomX Therapeutics stock price yearly change
-30.97%
year
CytomX Therapeutics key metrics
Market Cap | 83.73M |
Enterprise value | N/A |
P/E | -1.1 |
EV/Sales | -0.78 |
EV/EBITDA | 0.47 |
Price/Sales | 1.24 |
Price/Book | -1.28 |
PEG ratio | 0.06 |
EPS | 0.20 |
Revenue | 119.17M |
EBITDA | 12.38M |
Income | 16.53M |
Revenue Q/Q | 76.44% |
Revenue Y/Y | 100.21% |
Profit margin | -166.61% |
Oper. margin | -169.61% |
Gross margin | 20.53% |
EBIT margin | -169.61% |
EBITDA margin | 10.4% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCytomX Therapeutics stock price history
CytomX Therapeutics stock forecast
CytomX Therapeutics financial statements
Average Price Target
$3.5
Potential upside: 74.82%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 24.72M | -1.08M | -4.4% |
|---|---|---|---|
| Sep 2023 | 26.38M | 2.99M | 11.34% |
| Dec 2023 | 26.60M | 837K | 3.15% |
| Mar 2024 | 41.46M | 13.79M | 33.26% |
| Jun 2023 | 209185000 | 294.21M | 140.65% |
|---|---|---|---|
| Sep 2023 | 221167000 | 272.40M | 123.17% |
| Dec 2023 | 205151000 | 252.59M | 123.13% |
| Mar 2024 | 184687000 | 216.36M | 117.15% |
| Jun 2023 | -25.17M | 26.04M | 317K |
|---|---|---|---|
| Sep 2023 | -18.24M | -42.93M | 29.66M |
| Dec 2023 | -21.96M | 12.86M | 244K |
| Mar 2024 | -26.04M | 44.88M | 174K |
CytomX Therapeutics alternative data
| Sep 2023 | 116 |
|---|---|
| Oct 2023 | 116 |
| Nov 2023 | 116 |
| Dec 2023 | 116 |
| Jan 2024 | 116 |
| Feb 2024 | 116 |
| Mar 2024 | 120 |
| Apr 2024 | 120 |
| May 2024 | 120 |
| Jun 2024 | 120 |
| Jul 2024 | 120 |
CytomX Therapeutics other data
87.99%
-1.53%
of CTMX is owned by hedge funds
113
+4
53.64M
-933.90K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 28325 |
| Dec 2023 | 0 | 27772 |
| Mar 2024 | 0 | 47819 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MCCARTHY SEAN A. director, officer: CEO | Common Stock | 109,768 | $1.58 | $172,885 | ||
Option | MCCARTHY SEAN A. director, officer: CEO | Stock Option (Right to Buy) | 109,768 | $1.58 | $172,885 | ||
Sale | ROWLAND LLOYD A officer: General .. | Common Stock | 5,268 | $2.09 | $10,989 | ||
Sale | MCCARTHY SEAN A. director, officer: CEO | Common Stock | 20,223 | $2.09 | $42,185 | ||
Sale | OGDEN CHRISTOPHER officer: SVP, Finance and Accou.. | Common Stock | 2,971 | $2.09 | $6,198 | ||
Sale | BELVIN MARCIA officer: SVP, Chief Scientific .. | Common Stock | 12,795 | $2.09 | $26,690 | ||
Sale | LANDAU JEFFREY B officer: Chief Business Officer | Common Stock | 6,562 | $2.09 | $13,688 | ||
Sale | MCCARTHY SEAN A. director, officer: CEO | Common Stock | 13,551 | $1.38 | $18,714 | ||
Sale | BELVIN MARCIA officer: SVP, Chief Scientific .. | Common Stock | 4,077 | $1.38 | $5,630 | ||
Sale | LANDAU JEFFREY B officer: Chief Business Officer | Common Stock | 4,077 | $1.38 | $5,630 |
| Patent |
|---|
Application Filling date: 9 Nov 2021 Issue date: 4 Aug 2022 |
Application Filling date: 8 Nov 2021 Issue date: 28 Jul 2022 |
Application COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES Filling date: 26 Feb 2020 Issue date: 28 Jul 2022 |
Application METHODS AND COMPOSITIONS FOR DETERMINING THE BIODISTRIBUTION OF ACTIVATABLE ANTI-CD166 ANTIBODY CONJUGATES Filling date: 17 May 2020 Issue date: 21 Jul 2022 |
Grant Filling date: 9 Apr 2021 Issue date: 21 Jun 2022 |
Application Filling date: 10 Sep 2021 Issue date: 26 May 2022 |
Grant Filling date: 27 Dec 2018 Issue date: 19 Apr 2022 |
Application Filling date: 30 Apr 2021 Issue date: 31 Mar 2022 |
Application Filling date: 11 Aug 2021 Issue date: 24 Mar 2022 |
Application Filling date: 9 Apr 2021 Issue date: 24 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 11 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Sean A. McCarthy D.Phil., DPHIL (1967) Chairman, Chief Executive Officer & Pres | $957,000 |
| Dr. Amy C. Peterson M.D. (1967) Executive Vice President & Chief Devel. Officer | $804,800 |
| Mr. Carlos Campoy (1965) Senior Vice President & Chief Financial Officer | $768,780 |
| Dr. Alison L. Hannah M.D. (1961) Senior Vice President & Chief Medical Officer | $654,560 |
| Mr. Lloyd A. Rowland Jr., J.D. (1957) Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec. | $574,820 |
| Mr. Frederick W. Gluck (1935) Co-Founder & Independent Director | $50,500 |
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish?
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX: Pullbacks Are Opportunities
CytomX: Solving A Critical Problem In The High-Value ADC Space
-
What's the price of CytomX Therapeutics stock today?
One share of CytomX Therapeutics stock can currently be purchased for approximately $2.
-
When is CytomX Therapeutics's next earnings date?
Unfortunately, CytomX Therapeutics's (CTMX) next earnings date is currently unknown.
-
Does CytomX Therapeutics pay dividends?
No, CytomX Therapeutics does not pay dividends.
-
How much money does CytomX Therapeutics make?
CytomX Therapeutics has a market capitalization of 83.73M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 90.38% to 101.21M US dollars.
-
What is CytomX Therapeutics's stock symbol?
CytomX Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CTMX".
-
What is CytomX Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CytomX Therapeutics?
Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CytomX Therapeutics's key executives?
CytomX Therapeutics's management team includes the following people:
- Dr. Sean A. McCarthy D.Phil., DPHIL Chairman, Chief Executive Officer & Pres(age: 58, pay: $957,000)
- Dr. Amy C. Peterson M.D. Executive Vice President & Chief Devel. Officer(age: 58, pay: $804,800)
- Mr. Carlos Campoy Senior Vice President & Chief Financial Officer(age: 60, pay: $768,780)
- Dr. Alison L. Hannah M.D. Senior Vice President & Chief Medical Officer(age: 64, pay: $654,560)
- Mr. Lloyd A. Rowland Jr., J.D. Senior Vice President, Gen. Counsel, Chief Compliance Officer & Sec.(age: 68, pay: $574,820)
- Mr. Frederick W. Gluck Co-Founder & Independent Director(age: 90, pay: $50,500)
-
Is CytomX Therapeutics founder-led company?
Yes, CytomX Therapeutics is a company led by its founder Mr. Frederick W. Gluck.
-
How many employees does CytomX Therapeutics have?
As Jul 2024, CytomX Therapeutics employs 120 workers.
-
When CytomX Therapeutics went public?
CytomX Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 8 Oct 2015.
-
What is CytomX Therapeutics's official website?
The official website for CytomX Therapeutics is cytomx.com.
-
Where are CytomX Therapeutics's headquarters?
CytomX Therapeutics is headquartered at 151 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact CytomX Therapeutics?
CytomX Therapeutics's mailing address is 151 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 05153185.
-
What is CytomX Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for CytomX Therapeutics in the last 12 months, the avarage price target is $3.5. The average price target represents a 74.82% change from the last price of $2.
CytomX Therapeutics company profile:
CytomX Therapeutics, Inc.
cytomx.comExchange:
NASDAQ
Full time employees:
120
Industry:
Biotechnology
Sector:
Healthcare
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
151 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001501989
ISIN: US23284F1057
CUSIP: 23284F105
